Compare DexCom, Inc. (DXCM) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs QUALCOMM, Inc. — how do they compare? DexCom, Inc. trades at $77.54 (market cap $28.06B), while QUALCOMM, Inc. trades at $172.19 (market cap $187.59B). The key difference: QUALCOMM, Inc. is far larger — about 6.7× DexCom, Inc.'s market cap, and QUALCOMM, Inc. pays a 2.07% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | QCOM | |
|---|---|---|
Market Cap | $28.06B | $187.59B |
Sector | Health | Technology |
52-Week High | $89.53 | $251.10 |
52-Week Low | $54.84 | $124.07 |
Enterprise Value | $27.03B | $193.06B |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Qualcomm (QCOM) trades at $178.08, down 3.21% today, amid a bearish technical signal and mixed sentiment. Recent earnings have consistently beaten estimates, with Q1 2026 EPS of $2.65 surpassing the $2.56 forecast. The company maintains strong profitability with a 54.8% gross margin and 22.31% net income margin, while diversifying into AI and automotive markets. News highlights Nvidia's entry into the PC chip market increasing competitive pressures.
The outlook is cautiously optimistic with a consensus price target of $222.53 implying 25% upside, but near-term risks include smartphone demand softness and margin pressures. Long-term growth hinges on successful expansion in AI and data centers, though competition and market volatility pose challenges to shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
